Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37560
Titel: IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma
VerfasserIn: Struckmeier, Ann-Kristin
Radermacher, Anne
Fehrenz, Michael
Bellin, Tamara
Alansary, Dalia
Wartenberg, Philipp
Boehm, Ulrich
Wagner, Mathias
Scheller, Anja
Hess, Jochen
Moratin, Julius
Freudlsperger, Christian
Hoffmann, Jürgen
Thurner, Lorenz
Roemer, Klaus
Freier, Kolja
Horn, Dominik
Sprache: Englisch
Titel: Journal of Cancer Research and Clinical Oncology
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2022
Freie Schlagwörter: IDO
Oral squamous cell carcinoma (OSCC)
Macrophage
Tumour microenvironment
Immunotherapy
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Purpose Strategies for Indolamine-2,3-dioxygenase 1 (IDO1) inhibition in cancer immunotherapy once produced encouraging results, but failed in clinical trials. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance. Methods In this study, we investigated the signifcance of IDO1 expressing immune cells in primary tumours and corresponding lymph node metastases (LNMs) in oral squamous cell carcinoma (OSCC) by immunohistochemistry. The link between IDO1 and macrophages was investigated by fow cytometry in tumour tissue, healthy adjacent tissue and peripheral blood mononuclear cells (PBMCs). IDO1 activity (measured as Kynurenine/Tryptophan ratio) was assessed by ELISAs. Results High IDO1 expression in tumour-infltrating immune cells was signifcantly correlated with advanced stages [Spearman’s rank correlation (SRC), p=0.027] and reduced progression-free survival (multivariate Cox regression, p=0.034). IDO1 was signifcantly higher expressed in PBMCs of patients in advanced stages than in healthy controls (ANOVA, p<0.05) and IDO1+ macrophages were more abundant in intratumoural areas than peritumoural (t test, p<0.001). IDO1 expression in PBMCs was signifcantly correlated with IDO1 activity in serum (SRC, p<0.05). IDO1 activity was signifcantly higher in patients with LNMs (t test, p<0.01). Conclusion All in all, IDO1 expressing immune cells, especially macrophages, are more abundant in advanced stages of OSCC and are associated with reduced progression-free survival. Further investigations are needed to explore their role in local and systemic immune response. The IDO1 activity might be a suitable biomarker of metastasis in OSCC patients.
DOI der Erstveröffentlichung: 10.1007/s00432-022-04277-7
URL der Erstveröffentlichung: https://link.springer.com/article/10.1007/s00432-022-04277-7
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-375601
hdl:20.500.11880/33982
http://dx.doi.org/10.22028/D291-37560
ISSN: 1432-1335
0171-5216
Datum des Eintrags: 12-Okt-2022
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Information
In Beziehung stehendes Objekt: https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-022-04277-7/MediaObjects/432_2022_4277_MOESM1_ESM.docx
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Augenheilkunde
M - Biophysik
M - Experimentelle und Klinische Pharmakologie und Toxikologie
M - Innere Medizin
M - Pathologie
M - Physiologie
M - Zahn-, Mund- und Kieferheilkunde
Professur: M - Prof. Dr. Ulrich Boehm
M - Prof. Dr. Kolja Freier
M - Prof. Dr. Frank Kirchhoff
M - Prof. Dr. Berthold Seitz
M - Dr. med. Lorenz Thurner
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s00432-022-04277-7.pdf999,11 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons